{
  "success": true,
  "sourceFile": "C:\\Users\\panik\\Documents\\GitHub\\Protcol2USDMv3\\input\\trial\\NCT02967692_DREAMM2\\NCT02967692_DREAMM2_SAP.pdf",
  "pagesUsed": [
    0,
    1,
    2,
    3,
    4,
    5,
    6,
    7,
    8,
    9,
    10,
    11,
    12,
    13,
    14,
    15
  ],
  "modelUsed": "gemini-3-flash-preview",
  "sapData": {
    "analysisPopulations": [
      {
        "id": "pop_1",
        "name": "Full Analysis Set",
        "text": "Unless otherwise stated, all definitions and analysis methods are the same as given in the SAP used for the primary analysis of the study. Please refer to the final PFS analysis SAP for Part 3 (CPDR001F2301 Statistical Analysis Plan (SAP) for Part 3_Amendment3_Final) and Part 1 and 2 (CPDR001F2301 Statistical Analysis Plan (SAP) for Part 1 and 2_Amendment3_Final).",
        "populationType": "Efficacy",
        "instanceType": "AnalysisPopulation",
        "label": "FAS",
        "populationDescription": "Unless otherwise stated, all definitions and analysis methods are the same as given in the SAP used for the primary analysis of the study. Please refer to the final PFS analysis SAP for Part 3 (CPDR001F2301 Statistical Analysis Plan (SAP) for Part 3_Amendment3_Final) and Part 1 and 2 (CPDR001F2301 Statistical Analysis Plan (SAP) for Part 1 and 2_Amendment3_Final).",
        "criteria": "Refer to primary analysis SAP (PFS analysis SAP) for Part 1, 2, and 3"
      },
      {
        "id": "pop_2",
        "name": "Safety Analysis Set",
        "text": "Unless otherwise stated, all definitions and analysis methods are the same as given in the SAP used for the primary analysis of the study. Please refer to the final PFS analysis SAP for Part 3 (CPDR001F2301 Statistical Analysis Plan (SAP) for Part 3_Amendment3_Final) and Part 1 and 2 (CPDR001F2301 Statistical Analysis Plan (SAP) for Part 1 and 2_Amendment3_Final).",
        "populationType": "Safety",
        "instanceType": "AnalysisPopulation",
        "label": "SAF",
        "populationDescription": "Unless otherwise stated, all definitions and analysis methods are the same as given in the SAP used for the primary analysis of the study. Please refer to the final PFS analysis SAP for Part 3 (CPDR001F2301 Statistical Analysis Plan (SAP) for Part 3_Amendment3_Final) and Part 1 and 2 (CPDR001F2301 Statistical Analysis Plan (SAP) for Part 1 and 2_Amendment3_Final).",
        "criteria": "Refer to primary analysis SAP (PFS analysis SAP) for Part 1, 2, and 3"
      },
      {
        "id": "pop_3",
        "name": "Per-Protocol Set",
        "text": "Unless otherwise stated, all definitions and analysis methods are the same as given in the SAP used for the primary analysis of the study. Please refer to the final PFS analysis SAP for Part 3 (CPDR001F2301 Statistical Analysis Plan (SAP) for Part 3_Amendment3_Final).",
        "populationType": "Efficacy",
        "instanceType": "AnalysisPopulation",
        "label": "PPS",
        "populationDescription": "Unless otherwise stated, all definitions and analysis methods are the same as given in the SAP used for the primary analysis of the study. Please refer to the final PFS analysis SAP for Part 3 (CPDR001F2301 Statistical Analysis Plan (SAP) for Part 3_Amendment3_Final).",
        "criteria": "Refer to primary analysis SAP (PFS analysis SAP) for Part 3"
      }
    ],
    "characteristics": [
      {
        "id": "char_1",
        "name": "Overall Survival",
        "code": "OVERALL_SURVIVAL",
        "codeSystem": "http://www.cdisc.org/baseline-characteristics",
        "codeSystemVersion": "2024-03-29",
        "decode": "Overall Survival",
        "dataType": "Numeric",
        "instanceType": "Characteristic",
        "description": "Time from randomization to death due to any cause"
      },
      {
        "id": "char_2",
        "name": "Adverse Events",
        "code": "ADVERSE_EVENTS",
        "codeSystem": "http://www.cdisc.org/baseline-characteristics",
        "codeSystemVersion": "2024-03-29",
        "decode": "Adverse Events",
        "dataType": "Categorical",
        "instanceType": "Characteristic",
        "description": "Summary of adverse events including SOC, PT, relationship to treatment, and seriousness"
      },
      {
        "id": "char_3",
        "name": "PD-L1 expression status",
        "code": "PD-L1_EXPRESSION_STA",
        "codeSystem": "http://www.cdisc.org/baseline-characteristics",
        "codeSystemVersion": "2024-03-29",
        "decode": "PD-L1 expression status",
        "dataType": "Categorical",
        "instanceType": "Characteristic",
        "description": "Biomarker subgroup based on PD-L1 expression in tumor cells"
      },
      {
        "id": "char_4",
        "name": "Tumor Mutational Burden",
        "code": "TUMOR_MUTATIONAL_BUR",
        "codeSystem": "http://www.cdisc.org/baseline-characteristics",
        "codeSystemVersion": "2024-03-29",
        "decode": "Tumor Mutational Burden",
        "dataType": "Numeric",
        "instanceType": "Characteristic",
        "description": "Biomarker subgroup based on TMB (< 10 mut/Mb vs others)"
      }
    ],
    "summary": {
      "populationCount": 3,
      "characteristicCount": 4
    }
  }
}